An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
A phase 1/2 trial of TCC1727 tablet 90mg in non-small-cell lung cancer, gastric & gastro-oesophageal junction cancer, endometrial cancer and melanoma, run by Beijing Tide Pharmaceutical Co., Ltd, now recruiting.
Overview
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07371663 by Beijing Tide Pharmaceutical Co., Ltd, with 266 participants planned, started 2025-12-03 and due to reach its primary completion in 2028-09-30. Interventions recorded: TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg and benmelstobart Injection.
Similar pages
not linked directly; found by shared links- TrialA Phase I/II Clinical Study in Patients with Advanced Solid Tumor.
Shares Beijing Tide Pharmaceutical and the tag pipeline.
- TrialPsilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Shares Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Melanoma and the tag pipeline.
- TrialStudy of GV20-0251 in Participants With Solid Tumor Malignancies
Shares Endometrial cancer, Melanoma, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Shares Endometrial cancer, Melanoma, Non-small-cell lung cancer and the tag pipeline.
- TrialIntratumoral N17350 in Advanced Solid Tumors
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Shares Endometrial cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialPhase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
Shares Gastric & gastro-oesophageal junction cancer, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.